Clinical trials: Tumor Pancreas
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
- Conditions
- Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05795595
- Testing
- CTX131
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- CRISPR Therapeutics AG
Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors
FTT PET/CT in Pancreatic Neuroendocrine Tumors
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, [18F]FluorThanatrace ([18F]FTT).
- Trial name
- NCT07114939
- Testing
- [18F]FluorThanatrace
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Cancer
Contrast-enhanced Ultrasound and Pancreatic Lesions
The characterization of pancreatic lesions is one of the fundamental steps in the management of pancreatic neoplastic diseases. In terms of a subjective assessment of vascular enhancement in the various examination stages, the…
- Trial name
- NCT05977777
- Testing
- Contrast- enhanced ultrasound
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pancreas Cancer, Pancreatectomy
Gastric Venous Reconstruction After Total Pancreatectomy
Total pancreatoduodenectomy (TP) is the standard surgical approach for treatment of extended pancreas tumors. If the gastric coronary vein has to be sacrificed for oncologic or for technical reasons in total pancreatectomy with…
- Trial name
- GENDER (NCT04850430)
- Testing
- Gastric venous reconstruction
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Pancreatic Cancer
Safety and Efficacy Study of 90Y-hPAM4 at Different Doses
Safety study to determine highest dose of 90Y-hPAM4 can be safety administered
- Trial name
- NCT00597129
- Testing
- 90Y-hPAM4
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib and gemcitabine in treating patients with pancreatic cancer or other solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00462553
- Testing
- sunitinib malate, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Liver Cancer
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical…
- Conditions
- Breast Cancer, Liver Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- ESCAT (NCT06958224)
- Testing
- Large and early multigene sequencing
- Where
- France
- Volunteers
- 360 people
- Sponsor
- University Hospital, Lille
Pancreas Cancer, Non-Resectable Pancreas Carcinoma
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable pancreatic cancer, who are unfit for full-dose combination…
- Trial name
- NCT05841420
- Testing
- Gemcitabine, Nab paclitaxel
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Morten Ladekarl
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Pancreatic Cancer
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
The goal of this clinical research study is to learn if the study drug SOM 230 in addition to standard therapy of gemcitabine can shrink or slow the growth of pancreatic cancer.
- Trial name
- NCT01385956
- Testing
- SOM 230 LAR, Gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Treatment
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (<70Gy Vs.>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the…
- Trial name
- NCT04603586
- Testing
- SBRT, Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 119 people
- Sponsor
- Changhai Hospital
Metastatic Pancreatic Adenocarcinoma
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.
- Trial name
- NCT01124786
- Testing
- CO-1.01, Gemcitabine
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Clovis Oncology, Inc.
Advanced Pancreatic Adenocarcinoma
A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)
This study will determine whether [18F]-fluorodeoxyglucose-positron emission tomography (FDG-PET) can be used to screen for the activity of novel pancreatic cancer treatments.
- Trial name
- NCT01050283
- Testing
- Comparator: [18F]-FDG PET/CT and Volumetric CT
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Pancreatic Neoplasms
Prospective Study FNB, Is It Time To Abandon Cytological Assessment
Endoscopic Ultrasound (EUS) is a minimally invasive procedure used by gastroenterologists to examine pancreatic masses and lesions.
- Trial name
- (FACET) (NCT04165018)
- Testing
- Fine-Needle Biopsy (FNB)
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Baylor College of Medicine
Pancreas Cancer
Registry Study - Whipple at the Splenic Artery
The purpose of this study is to determine how effective Whipple at the Splenic Artery (WATSA).
- Trial name
- WATSA (NCT01155882)
- Testing
- Whipple at the Splenic Artery (WATSA)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer
A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
Pancreatic carcinoma typically has a high recurrence rate and very poor prognosis. Surgery is the best choice for the treatment of pancreatic cancer, but for those advanced pancreatic cancer patients，when surgery is not…
- Trial name
- meso-CART (NCT02706782)
- Testing
- TAI-meso-CART
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai GeneChem Co., Ltd.
Pancreatic Cancer
Fatigue and Pancreas and Bile Duct Cancer Study
The purpose of this pilot study is to determine the effects of a walking program on fatigue, physical functioning and QOL in patients with pancreatic and periampullary cancers who have had surgery or are undergoing adjuvant…
- Trial name
- NCT00902759
- Testing
- Walking Program
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Pancreatic Neoplasms
Textbook Outcome as a Composite Outcome Measure in Laparoscopic Pancreaticoduodenectomy
This is a multicenter, retrospective, observational study. Textbook outcome is a composite outcome measure for surgical quality assessment.
- Trial name
- NCT05616403
- Testing
- No intervention
- Where
- China
- Volunteers
- 1,029 people
- Sponsor
- Tongji Hospital
Mediastinal Tumours and Lymph Nodes, Celiac, Perigastric and Peri-pancreatic Lymph Nodes
Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles (FNA-22G-25G)
The aim of the study is to compare the performance characteristics of EUS-FNA 22 Gauge needle and EUS FNA 25 Gauge needle in terms of cellularity and diagnostic yield for diagnosis of various pathologies, including lymph nodes…
- Conditions
- Mediastinal Tumours and Lymph Nodes, Celiac, Perigastric and Peri-pancreatic Lymph Nodes, Pancreatic Masses, Liver Masses
- Trial name
- NCT01016288
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 135 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.